tested DNX-2401 in combination with intravenous pembrolizumab (PD-1 immune checkpoint inhibitor) in patients with recurrent glioma and the findings showed that treatment of glioma with combination of DNX-2401 and pembrolizumab significantly improves the disease burden (178). This evidence concerns the gene PDCD1 and glioma.